Mylan to buy Meda in further generics consolidation

Generic pharmaceuticals company Mylan has agreed to buy Swedish firm Meda in a deal worth SEK83.6 billion (£6.9 billion) in cash, shares and assumed debt. Meda claims the move will expand the combined company’s US presence to ‘critical mass’.  This is the latest of a series of deals that have seen a significant consolidation of the generic drugs industry.

Mylan was recently involved in a three way takeover battle as it simultaneously tried to fend off a takeover bid from Israeli generics giant Teva, while making its own hostile bid for Irish drugmaker Perrigo. The bids were eventually scrapped as Teva diverted to buy the generics arm of Allergan, and Perrigo shareholders rejected the takeover deal, leading Mylan to buy back up to $1 billion of its own shares.

Related Content

Mylan expands in dermatology

18 May 2016 Business

news image

$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio

Perrigo nabs US rights to AZ Crohn’s drug

8 December 2015 Business

news image

Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio

Most Commented

New antibiotic picked from nose bacteria

27 July 2016 Research

news image

Discovery suggests human microbiome may be an untapped source of antimicrobial compounds

Perovskite boosts silicon solar cell efficiency

25 November 2015 News and Analysis

news image

Silicon industry will be ‘beating a path to the door’ of inventors, says scientist